Hyderabad, May 18 (PTI) Ocugen, a USA-based biotechnology company is planning to establish a research and development (R&D) centre in Telangana that will focus on developing cutting-edge modifier gene therapies and regenerative cell therapy targeting unmet medical needs, and vaccines to support public health.

An official release said the centre will make a positive economic impact in the region and provide a significant number of jobs over the next few years.

Also Read | BSE Odisha Announces Class 10 Results, Overall Pass Percentage at 96.19.

The announcement was made after Telangana Minister K T Rama Rao's meeting with Dr Shankar Musunuri, Chairman, CEO and Co-founder of Ocugen and others in USA.

"We look forward to expanding operations in India and beginning to transform Ocugen into a truly global organisation as we pursue new approaches to medicine—being bold and thinking differently with patients at the centre of everything we do. We are grateful for this opportunity, and it has been a pleasure collaborating with the Telangana authorities," Musunuri said.

Also Read | MHADA Mumbai Board Lottery 2023: Registration Begins From July 18 For 4,083 Houses Up for Sale, Know Draw Result Date and How to Apply Online at lottery.mhada.gov.in.

Rama Rao said, "I'm delighted to welcome Ocugen to Hyderabad. This is a testament to the vibrant biotech industry and a strong academic base in the state that has attracted both local and international players to establish research and development centers."

Ocugen is Bharat Biotech's partner in USA and Canada for the latter's Covid-19 vaccine Covaxin.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)